Diabetes Treatment Flashcards

1
Q

treatment of diabetes mellitus - general principles

A

*all pts with DM should receive education on diet, exercise, blood glucose monitoring, and complication management
*pts with T1DM will all require insulin therapy
*pts with T2DM: threshold varies clinically, but generally A1c < 7.5% in asymptomatic pt, start with lifestyle changes before medical therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

treatment of diabetes mellitus - goals of tx

A

*goal 1 = restore euglycemia (HbA1c of 7.0% or less)
-adjusted based on patient’s age, risk of hypoglycemia, comorbidities
*goal 2 = reduce complications associated with uncontrolled blood sugars

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

glucose monitoring

A

*HbA1c is measured every 3 months
*glucose monitoring by the patient is needed for more immediate feedback:
1. fingerstick checks
2. continuous glucose monitors
*generally, aim for blood glucose between 70-180 mg/dL the majority of the time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

insulin - overview

A

*essential for treatment of T1DM
*can also be used for T2DM and gestational diabetes, when needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

insulin - MOA

A

*same as endogenous insulin; binds insulin receptor (tyrosine kinase activity):
1. stimulates cellular uptake of glucose
2. liver: stores glucose to glycogen
3. muscle: increase glycogen & protein synthesis
4. fat: increases triglyceride storage
5. cell membrane: increase K+ uptake (shift K+ into cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

insulin - metabolism/excretion

A

*renally excreted
*will remain long in the body/have longer lasting effects in pts with CKD/ESRD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

rapid acting insulin products

A

*lispro, aspart, glulisine
*onset = 5-15 min
*peak = 30-90 min
*duration = 4 hr
*a type of bolus insulin (given at mealtime)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

short acting insulin products

A

*regular insulin
*onset = 30-60 min
*peak = 2-3 hrs
*duration = 5-8 hrs
*a type of bolus insulin (given at mealtime)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

basal (long-acting) insulin products

A

*detemir, glargine, degludec
*onset = 2 hrs
*peak = no peak; basal control
*duration = 20-24 hours
*acts as our background insulin (baseline insulin present to cover gluconeogenesis from liver when fasting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

example insulin regimen

A

*glargine (long-acting basal insulin) 30 units once daily AND lispro (rapid-acting bolus insulin) 10 units 3x daily before meals

note - rapid and short-acting insulin should be administered 15 min before meals due to time of onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

insulin - ADEs

A

hypoglycemia** (most dangerous side effect of insulin; can lead to coma or death if severe)
**
weight gain:
increased glucose uptake in muscle & adipose tissue; excess glucose is converted to glycerol and triglycerides → weight gain
*lipohypertrophy: repeated insulin injections in same site → lumps of scar tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

glucagon - overview

A

*should always be prescribed with insulin
*administered when pt is having hypoglycemia and unable to tolerate oral glucose (unconscious, vomiting, etc)
*MOA: works by rapidly increased glycogenolysis
*also has antagonist effects on glucose uptake by liver cells and increases gluconeogenesis
*injectable or nasal spray formulations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

metformin - indications, MOA

A

*indication: commonly first line for T2DM
*MOA: enhances cellular glucose uptake (induces GLUT-4 expression), reduce liver gluconeogenesis and intestinal glucose absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

metformin - advantages & disadvantages

A

*pros: weight loss, lower LDL, lower triglyceride levels, lower BP, low risk for hypoglycemia, improves cardiovascular risk

*cons: nausea, diarrhea, metallic taste, lactic acidosis (caution/do not use in CKD, severe CHF, liver disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

thiazolidinediones (TZD) - examples, indications, MOA

A

*pioglitazone, rosiglitazone
*second or third line DM treatment
*indication: used to intensify therapy
*MOA: increase insulin sensitivity by activating a group of nuclear receptors (PPAR-gamma); the cell stores fatty acids (making these less available for energy use) so is forced to use glucose instead, which lowers glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

thiazolidinediones (TZD) - advantages & disadvantages

A

*pioglitazone, rosiglitazone
*pros: mild GI side effects, can be used in CKD
*cons: fluid retention, heart failure, liver damage, decreased bone density, bladder cancer

17
Q

GLP-1 agonists - examples, indications, MOA

A

*semaglutide, dulaglutide, liraglutide, exanatide
*aka incretin mimics
*indication: can be first or second line for DM
*MOA: bind to GLP-1 receptor and mimic endogenous GLP-1
-GLP-1 is an incretin hormone secreted by intestinal cells after a meal
-cause increased postprandial insulin secretion, decrease glucagon delay, delay gastric emptying, increase satiety

18
Q

GLP-1 agonists - advantages

A

*weight loss
*reduce cardiac events
*renal protection in CKD
*rare hypoglycemia

19
Q

GLP-1 agonists - disadvantages

A

*mostly come in injectable forms
*GI upset
*contraindication in MEN2a or 2b/medullary thyroid cancer
*relative contraindication in pancreatitis

20
Q

DPP-4 inhibitors - examples, indication, MOA

A

*sitagliptin, saxagliptin, linagliptin
*indication: second line for DM
*MOA: bind to and inactivate the enzyme DPP-4
-DPP-4 degrades GLP1, so these medications increase endogenous levels of GLP-1
*effects are similar to GLP-1 agonists, but much less potent
*no hypoglycemia, generally few side effects

21
Q

sulfonylureas - examples, indications

A

*glipizide, glyburide, chlorpropamide, tolbutamide
*indications: historically first line, rarely used now

22
Q

sulfonylureas - MOA

A

*glipizide, glyburide, chlorpropamide, tolbutamide
*MOA: stimulate pancreatic insulin release by closing ATP-sensitive potassium channels in the beta cell plasma membrane → depolarizes the cell → influx of calcium → insulin release independent of food intake

23
Q

sulfonylureas - pros and cons

A

*pros: cheap
*cons: high risk of hypoglycemia, early onset dementia in geriatric pts, weight gain
*use with caution in elderly and pts with CKD

24
Q

SGLT2 inhibitors - examples, indications

A

*canagliflozin, empagliflozin, dapagliflozin
*indication: second line DM treatment (can be first line depending on presence of CHF, CKD(

25
Q

SGLT2 inhibitors - MOA

A

*canagliflozin, empagliflozin, dapagliflozin
*MOA: inhibit glucose reabsorption in the proximal tubule by blocking SGLT2 transporters → urinary excretion of glucose

26
Q

SGLT2 inhibitors - pros and cons

A

*pros: secondary prevention of CV events, renal protection in CKD
*cons: UTI, dehydration, genital candida infections, hypoglycemia, AKI, euglycemic DKA

27
Q

other non-insulin medications that could be used in diabetes

A

*repaglinide
*pramlintide
*alpha-glucosidase inhibitors (acarbose); ADEs = bloating and flatulence